Two of longevity's best-known molecules just got tested together on aging bone, and the pairing did something neither managed as well alone. The catch: this was done in old mice and in cells, not in people.
A team from Nanjing Gaochun People's Hospital reports in Molecular Biology Reports (2026) that combining metformin and taurine slowed age-related bone loss in 18-month-old mice. It also kept their bone marrow stem cells working better than either compound given by itself.
What the researchers did
The team used 18-month-old male C57BL/6J mice, an age that is old for the strain. The animals received metformin, taurine, or both for eight consecutive weeks.
Bone structure was assessed with micro-computed tomography and histological staining. The researchers also isolated bone marrow mesenchymal stem cells (BMSCs) from the aged mice. These cells give rise to bone-forming osteoblasts, and their decline is closely linked to age-related bone loss. The team measured:
- Osteogenic (bone-forming) differentiation
- Proliferative capacity
- Senescence-related changes
- Inflammatory cytokine production
They then ran transcriptomic analysis to see which gene networks shifted. Finally, they used siRNA to knock down one candidate gene, Crebrf, to test whether it mattered.
What they found
Better bone. The combination improved bone mass and trabecular microarchitecture more effectively than either single treatment. Histology showed better-preserved trabecular structure and more collagen-rich matrix in the combination group.
Healthier stem cells. BMSCs from combination-treated mice showed:
- Stronger osteogenic differentiation
- Higher proliferative activity
- Fewer senescence-associated features
- Improved inflammatory homeostasis
A broad molecular signature. Transcriptomics pointed to coordinated changes in genes tied to proliferation, senescence, metabolism, proteostasis and genome maintenance. That is a wide net, and it fits the idea that the combination acts on several aging-related processes at once.
A candidate mediator. Crebrf emerged as a possible regulator. Knocking it down in BMSCs weakened the anti-senescent and cellular-stability effects of the combination. That suggests Crebrf contributes to the benefit, though the abstract calls it a "candidate mediator," not a proven master switch.
Why taurine gets so much attention
Taurine is an amino-acid-like compound found in the body and in many foods, and a common ingredient in energy drinks and supplements. It became a longevity talking point after a 2023 Science study reported that taurine levels fall with age and that supplementation improved health measures and extended lifespan in mice. Interest then spread to supplement shelves and social media.
The enthusiasm has outrun the evidence. Later work has debated how consistently taurine declines with age, and whether low taurine drives aging or simply tracks with it. No large human trial has shown that taurine supplements slow aging or prevent fractures.
Metformin has a longer track record. It is a decades-old diabetes drug, and researchers have long explored it as an aging-modulating agent because of its effects on metabolism and cellular stress pathways. Its potential as an anti-aging drug in healthy people is still unproven.
This new study sits in that context. It is a tidy test of whether two much-discussed compounds are better together, in one tissue, in one animal model.
Limits you should not skip
This is preclinical work, and the limits are substantial.
- Mice, not humans. Results in mice often fail to translate to people.
- Male mice of one strain. The abstract describes only male C57BL/6J animals, so we don't know whether females or other strains respond the same way.
- Short treatment. Eight weeks shows an effect over a limited window. It says nothing about long-term safety or durability.
- Cell-level mechanism work is still early. Crebrf is a candidate, and knockdown in cultured BMSCs does not prove how the combination works in a living animal.
- Bone structure is not fracture risk. Better microarchitecture on imaging is encouraging, but the abstract does not report fractures or mechanical strength outcomes.
- Single-center report. The authors declare no conflicts of interest, but independent replication would strengthen the findings.
Practical takeaways
Dose and timing: The abstract does not give doses, and mouse doses cannot be converted into a human regimen from this information. There is no evidence-based human dose or schedule for this combination for bone health.
Who it's for: Right now, nobody outside a research setting. Metformin is a prescription drug with its own risks and side effects, so combining it with supplements to protect bones is not supported by this study. People worried about osteoporosis should talk to a clinician about established approaches, such as bone density screening, adequate calcium and vitamin D, resistance and impact exercise, and approved therapies where appropriate.
What to watch: Look for replication in female and other mouse models, strength and fracture endpoints, and eventually human studies. The Crebrf finding is also worth following, since it hints at a pathway that could be targeted on its own.
The bottom line
The study offers a hypothesis worth testing: that pairing metformin with taurine can better protect aging bone and its stem cell supply than either compound alone. For now, it is a promising mouse and cell-culture result, not a reason to change what you take.